Impaired replication of protease inhibitor-resistant HIV-1 in human thymus

Nature Medicine

Volumn 7, Issue 6, 2001, Pages 712-718

  Stoddart, Cheryl A ^a   Liegler, Teri J ^a   Mammano, Fabrizio ^b   Linquist Stepps, Valerie D ^a   Hayden, Matthew S ^a   Deeks, Steven G ^c   Grant, Robert M ^a,c   Clavel, François ^b   Mccune, Joseph M ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BICHAT HOSPITAL   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL COUNT; CLONING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTOPOIESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; T LYMPHOCYTE; THYMOCYTE; THYMUS; VIREMIA; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

ADULT; ANIMALS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MICROBIAL; FETAL TISSUE TRANSPLANTATION; FLOW CYTOMETRY; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MICE; MICE, SCID; MIDDLE AGED; ORGAN CULTURE TECHNIQUES; RECOMBINATION, GENETIC; T-LYMPHOCYTES; THYMUS GLAND; VIRAL LOAD; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0034948377     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/89090     Document Type: Article

References (41)

1. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
2. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-Week follow-up
3. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
4. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
5. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV cohort study
6. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators
7. + T cell homeostasis and function in advanced HIV disease
8. Genetic correlates of in viva viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
9. In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds
10. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
11. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
12. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease
13. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study
14. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen
15. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
16. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy
17. Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of resistance mutations in the presence and absence of the drug
18. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure
19. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors
20. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
21. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
22. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites
23. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
24. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
25. Primary and recombinant HIV-1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues
26. Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds
27. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
28. Protease inhibitor-resistant HIV-1 from patients with preserved CD4 counts is cytopathic in activated CD4 T lymphocytes
29. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection
30. + lymphocytes as prognostic markers of HIV-1 infection
31. + T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: Role of changes in thymic output and T cell death
32. Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease
33. Effect of recent thymic emigrants on progression of HIV-1 disease
34. Factors influencing T-cell turnover in HIV-1-seropositive patients
35. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy
36. Changes in thymic function with age and during the treatment of HIV infection
37. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy
38. Longterm human hematopoiesis in the SCID-hu mouse
39. The SCID-hu Thy/Liv mouse: An animal model for HIV-1 infection
40. Antiviral activity of 2′-deoxy-3′oxa-4′-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice
41. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment